We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic (MDT) Inks Deal to Focus on Value-Based Healthcare
Read MoreHide Full Article
Medtronic plc (MDT - Free Report) recently entered into a five-year collaborative agreement with health care organization ChristianaCare for the improvement of patient outcome in Delaware and its surroundings. Financial terms of the deal have been kept under wraps.
Per Medtronic, this initiative will also reduce healthcare costs.
The Deal at a Glance
Under this five-year contract, the companies will focus on implementing value-based healthcare initiatives over fee-for-service system as according to them, value-based care is the key to achieving optimal health at accessible and affordable price.
This effort will help ChristianaCare apply appropriate medical technologies and therapies to the targeted patients. With shared financial accountability between ChristianaCare and Medtronic, this will enhance health results at lower costs.
The first initiative of this joint effort targets to address opioid-induced ventilatory impairment (OIVI). OIVI occurs when opioids used for pain management, hinder the central drive to breathe and may cause the patient to go absolute breathless unless there is any life-saving measure to redress the problem. Under this initiative, patients at high risk of OIVI will be identified and administered with continuous monitoring technology to track breathing and help alert the care team about any abnormal trends.
Other initiatives of the deal are expected to address heart failure and diabetes, two most common causes of death each year. Per the Centers for Disease Control and Prevention, these two ailments together affect more than 35 million people in the United States and burden the nation with an estimated $357 billion expense annually. The alliance aims at boosting ChristianaCare’s ability to prevent or slow down disease progression, curb frequent hospitalizations and trim overall cost of care for patients afflicted with these chronic conditions.
Is the Deal Strategic Fit?
With this collaboration, Medtronic will get access to ChristianaCare’s diverse patient population across a broad spectrum of healthcare settings and expand its customer base in Delaware and adjacent regions. This will provide an ideal testing ground for the company to develop and scale new value-based initiatives.
Price Performance
Over the past three months, shares of Medtronic have outperformed the industry it belongs to. The stock has rallied 4.7% versus the industry’s 0.7% decline.
Zacks Rank & Other Stocks Worth a Look
Medtronic carries a Zacks Rank #2 (Buy). A few other top-ranked stocks from the broader medical space are Haemonetics Corporation (HAE - Free Report) , NuVasive, Inc and ResMed (RMD - Free Report) . While ResMed sports a Zacks Rank #1 (Strong Buy), the other two carry the same top Zacks Rank as Medtronic. You can see the complete list of today’s Zacks #1 Rank stocks here.
Haemonetics has a projected long-term earnings growth rate of 13.5%.
NuVasive has an expected long-term earnings growth rate of 10.9%.
ResMed has a long-term earnings growth rate of 12.9%.
Free: Zacks’ Single Best Stock Set to Double
Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
Image: Bigstock
Medtronic (MDT) Inks Deal to Focus on Value-Based Healthcare
Medtronic plc (MDT - Free Report) recently entered into a five-year collaborative agreement with health care organization ChristianaCare for the improvement of patient outcome in Delaware and its surroundings. Financial terms of the deal have been kept under wraps.
Per Medtronic, this initiative will also reduce healthcare costs.
The Deal at a Glance
Under this five-year contract, the companies will focus on implementing value-based healthcare initiatives over fee-for-service system as according to them, value-based care is the key to achieving optimal health at accessible and affordable price.
This effort will help ChristianaCare apply appropriate medical technologies and therapies to the targeted patients. With shared financial accountability between ChristianaCare and Medtronic, this will enhance health results at lower costs.
The first initiative of this joint effort targets to address opioid-induced ventilatory impairment (OIVI). OIVI occurs when opioids used for pain management, hinder the central drive to breathe and may cause the patient to go absolute breathless unless there is any life-saving measure to redress the problem. Under this initiative, patients at high risk of OIVI will be identified and administered with continuous monitoring technology to track breathing and help alert the care team about any abnormal trends.
Other initiatives of the deal are expected to address heart failure and diabetes, two most common causes of death each year. Per the Centers for Disease Control and Prevention, these two ailments together affect more than 35 million people in the United States and burden the nation with an estimated $357 billion expense annually. The alliance aims at boosting ChristianaCare’s ability to prevent or slow down disease progression, curb frequent hospitalizations and trim overall cost of care for patients afflicted with these chronic conditions.
Is the Deal Strategic Fit?
With this collaboration, Medtronic will get access to ChristianaCare’s diverse patient population across a broad spectrum of healthcare settings and expand its customer base in Delaware and adjacent regions. This will provide an ideal testing ground for the company to develop and scale new value-based initiatives.
Price Performance
Over the past three months, shares of Medtronic have outperformed the industry it belongs to. The stock has rallied 4.7% versus the industry’s 0.7% decline.
Zacks Rank & Other Stocks Worth a Look
Medtronic carries a Zacks Rank #2 (Buy). A few other top-ranked stocks from the broader medical space are Haemonetics Corporation (HAE - Free Report) , NuVasive, Inc and ResMed (RMD - Free Report) . While ResMed sports a Zacks Rank #1 (Strong Buy), the other two carry the same top Zacks Rank as Medtronic. You can see the complete list of today’s Zacks #1 Rank stocks here.
Haemonetics has a projected long-term earnings growth rate of 13.5%.
NuVasive has an expected long-term earnings growth rate of 10.9%.
ResMed has a long-term earnings growth rate of 12.9%.
Free: Zacks’ Single Best Stock Set to Double
Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
See 5 Stocks Set to Double>>